ONC
The table below shows BeOne Medicines AG's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $1.13B | -$140.63M | -$1.16B | -$1.50B | -$1.30B | -$1.28B |
| Capital expenditure | $185.84M | $492.66M | $561.90M | $325.43M | $262.94M | $117.51M |
| Investing cash flow | -$276.15M | -$548.35M | $60.00M | $1.08B | $640.66M | -$3.17B |
| Dividends paid | - | - | - | - | - |
BeOne Medicines AG reported operating cash flow of $1.13B for fiscal year 2025. That is up 901.8% from -$140.63M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$89.51M (FY 2016) to $1.13B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $1.06B | $193.45M | $416.48M | -$18.97M | $3.64B | $5.20B |